Elutia Inc. (ELUT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Elutia Inc. (ELUT) has a cash flow conversion efficiency ratio of -0.348x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.83 Million) by net assets ($22.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Elutia Inc. stock valuation for the company's overall valuation and market capitalisation.
Elutia Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Elutia Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Elutia Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elutia Inc. ranked by their cash flow conversion efficiency. Explore Elutia Inc. cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DLP Resources Inc
V:DLP
|
-0.246x |
|
SJM Co Ltd
KO:123700
|
0.046x |
|
FreeMs Corporation
KQ:053160
|
-0.003x |
|
Inspirisys Solutions Limited
NSE:INSPIRISYS
|
0.188x |
|
Power Minerals Ltd
AU:PNN
|
-0.070x |
|
Oil Country Tubular Limited
NSE:OILCOUNTUB
|
0.069x |
|
Essar Shipping Limited
NSE:ESSARSHPNG
|
-0.003x |
|
Gamehaus Holdings Inc. Class A Ordinary Shares
NASDAQ:GMHS
|
-0.014x |
Annual Cash Flow Conversion Efficiency for Elutia Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Elutia Inc. from 2018 to 2025. View today's stock price for Elutia Inc. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.67 Million | $-44.81 Million | -1.619x | -430.63% |
| 2024-12-31 | $-46.26 Million | $-22.66 Million | 0.490x | -13.12% |
| 2023-12-31 | $-38.60 Million | $-21.76 Million | 0.564x | -86.76% |
| 2022-12-31 | $-5.03 Million | $-21.43 Million | 4.259x | +472.79% |
| 2021-12-31 | $13.52 Million | $-15.45 Million | -1.142x | -74.64% |
| 2020-12-31 | $20.83 Million | $-13.63 Million | -0.654x | -598.95% |
| 2019-12-31 | $-55.11 Million | $-7.22 Million | 0.131x | +11.03% |
| 2018-12-31 | $-43.41 Million | $-5.12 Million | 0.118x | -- |
About Elutia Inc.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDer… Read more